New horizons in systemic anti-cancer therapy in older people.
Cancer is a disease associated with ageing. Increased life expectancy means that cancer in older adults is becoming an increasingly common problem. There are unique issues to consider when making decisions about cancer treatment in older populations. Unfortunately, however, this group is still under...
| Publicado en: | Age & Ageing Vol. 47; no. 3; pp. 340 - 349 |
|---|---|
| Autores principales: | , , |
| Formato: | Artículo |
| Publicado: |
Oxford University Press / USA
May2018
|
| Materias: | |
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ssf&AN=129341157&site=ehost-live header: @attributes: shortDbName: ssf uiTerm: 129341157 longDbName: Social Sciences Full Text (H.W. Wilson) uiTag: AN controlInfo: bkinfo: jinfo: jid: 00020729 AGA jtl: Age & Ageing issn: 00020729 maglogo: N pubinfo: dt: May2018 vid: 47 iid: 3 pid: 622 pub: Oxford University Press / USA artinfo: ui: 129341157 10.1093/ageing/afy024 ppf: 340 ppct: 9 formats: tig: atl: New horizons in systemic anti-cancer therapy in older people. aug: au: PARRY, J. L. HALL, P. S. YOUNG, J. affil: Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh EH4 2XR, UK Bradford Institute for Health Research, Bradford Royal Infirmary, Bradford BD9 6RJ, UK su: Old age Cancer chemotherapy Drug tolerance Drug toxicity Tumors Patient selection sug: subj: Old age Cancer chemotherapy Drug tolerance Drug toxicity Tumors Patient selection keyword: cancer chemotherapy immunotherapy older people systemic anti-cancer therapy (SACT) targeted therapy toxicity trials cancer chemotherapy immunotherapy older people systemic anti-cancer therapy (SACT) targeted therapy toxicity trials ab: Cancer is a disease associated with ageing. Increased life expectancy means that cancer in older adults is becoming an increasingly common problem. There are unique issues to consider when making decisions about cancer treatment in older populations. Unfortunately, however, this group is still under-represented in clinical trials for new cancer therapies meaning there are less evidence-based data to guide management. This article aims to look at how we can optimise the cancer treatment for older patients with a focus on systemic anti-cancer therapy and addressing particular issues around patient selection, improving treatment tolerance and use of newer agents with different toxicity profiles. pubtype: Academic Journal doctype: Article src: R language: English refInfo: copyright: @attributes: flag: N holdings: @attributes: islocal: N |
|---|